115 related articles for article (PubMed ID: 28295672)
1. The prevalence of HPV infections in HPV-vaccinated women from the general population.
Hamsikova E; Smahelova J; Ludvikova V; Salakova M; Rychla J; Skrenkova J; Rob L; Tachezy R
APMIS; 2017 Jun; 125(6):585-595. PubMed ID: 28295672
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
[TBL] [Abstract][Full Text] [Related]
3. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
Sankaranarayanan R; Prabhu PR; Pawlita M; Gheit T; Bhatla N; Muwonge R; Nene BM; Esmy PO; Joshi S; Poli UR; Jivarajani P; Verma Y; Zomawia E; Siddiqi M; Shastri SS; Jayant K; Malvi SG; Lucas E; Michel A; Butt J; Vijayamma JM; Sankaran S; Kannan TP; Varghese R; Divate U; Thomas S; Joshi G; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Hingmire S; Kriplani A; Mishra G; Pimple S; Jadhav R; Sauvaget C; Tommasino M; Pillai MR;
Lancet Oncol; 2016 Jan; 17(1):67-77. PubMed ID: 26652797
[TBL] [Abstract][Full Text] [Related]
7. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors for human papillomavirus DNA in cervical cytology.
Kasap B; Yetimalar H; Keklik A; Yildiz A; Cukurova K; Soylu F
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):168-71. PubMed ID: 21764503
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
10. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.
Roteli-Martins CM; Naud P; De Borba P; Teixeira JC; De Carvalho NS; Zahaf T; Sanchez N; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2012 Mar; 8(3):390-7. PubMed ID: 22327492
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.
Olsson SE; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Hum Vaccin; 2009 Oct; 5(10):696-704. PubMed ID: 19855170
[TBL] [Abstract][Full Text] [Related]
13. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
Guo F; Hirth JM; Berenson AB
Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany.
Kovács K; Varnai AD; Bollmann M; Bankfalvi A; Szendy M; Speich N; Schmitt C; Pajor L; Bollmann R
J Med Virol; 2008 Oct; 80(10):1814-23. PubMed ID: 18712836
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands.
Mollers M; Boot Hein J; Vriend Henrike J; King Audrey J; van den Broek Ingrid VF; van Bergen Jan EA; Brink Antoinette AT; Wolffs Petra FG; Hoebe Christian JP; Meijer Chris JL; van der Sande Marianne AB; de Melker Hester E
Vaccine; 2013 Jan; 31(2):394-401. PubMed ID: 23146675
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of cervical human papillomavirus infection in healthy women is related to sexual behaviours and educational level: a cross-sectional study.
Tay SK; Oon LL
Int J STD AIDS; 2014 Dec; 25(14):1013-21. PubMed ID: 24648316
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
[TBL] [Abstract][Full Text] [Related]
18. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth.
Moscicki AB; Karalius B; Tassiopoulos K; Yao TJ; Jacobson DL; Patel K; Purswani M; Seage GR;
Clin Infect Dis; 2019 Sep; 69(7):1183-1191. PubMed ID: 30927547
[TBL] [Abstract][Full Text] [Related]
19. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
20. Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13-26 years) enrolled in the VALHIDATE study.
Orlando G; Fasolo M; Mazza F; Ricci E; Esposito S; Frati E; Zuccotti GV; Cetin I; Gramegna M; Rizzardini G; Tanzi E;
Hum Vaccin Immunother; 2014; 10(4):986-94. PubMed ID: 24423757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
